EDIGENE INC has a total of 22 patent applications. It increased the IP activity by 550.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), Taiwan and China. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are AGTC GENE TECHNOLOGY COMPANY L, INNOVIR LAB INC and NEW PORTAL LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | Taiwan | 5 | |
#3 | China | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | United States | 3 | |
#6 | Philippines | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Peptides | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Yuan Pengfei | 16 |
#2 | Fang Riguo | 13 |
#3 | Yu Lingling | 13 |
#4 | Wang Jia | 11 |
#5 | Liang Fucai | 9 |
#6 | Xia Penghui | 9 |
#7 | Yu Ling-Ling | 4 |
#8 | Wang Fei | 4 |
#9 | Dong Xi | 4 |
#10 | Yuan Peng-Fei | 4 |
Publication | Filing date | Title |
---|---|---|
WO2021043278A1 | Method for evaluating gene editing therapy based on off-target assessment | |
TW202100752A | Method for predicting the effectiveness of the treatment of hemoglobinopathies | |
WO2020221291A1 | Method for predicting effectiveness of treatment of hemoglobinopathy | |
TW202043249A | Methods and compositions for editing rnas | |
WO2019052577A1 | Gene editing t cell and use thereof | |
CN109722415A | A kind of cultural method for cultivating composition, culture medium and candidate stem cell of candidate stem cell |